)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Futura Medical
Futura Medical (FUM) investor relations material
Futura Medical H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary1 Sep, 2026
Executive summary
Achieved significant strategic progress, including evolving the commercial model, strengthening the IP portfolio, and advancing the development pipeline.
Completed a strategic review, shifting from a pure R&D/out-licensing model to a hybrid R&D and commercial approach for higher, sustainable margins.
Secured new US and China patents for EroxonⓇ and transitioned US commercial partnership from Haleon to MPG.
Advanced EroxonⓇ Intense and WSD4000, with positive clinical and user study results supporting commercial launches.
Financial highlights
Revenue for HY26 was £1.62 million (HY25: £1.00 million), with £1.40 million from a settlement with Haleon.
Gross profit rose to £1.62 million (HY25: £0.24 million), reflecting the Haleon settlement and low cost of goods.
Operating loss reduced to £1.20 million (HY25: £6.72 million); excluding prior period exceptional costs, HY25 operating loss was £2.67 million.
Adjusted operating loss before share-based payments was £0.82 million (HY25: £6.05 million).
Cash and cash equivalents at 30 June 2026 were £1.24 million (30 June 2025: £3.69 million).
Outlook and guidance
Current cash resources are expected to last until approximately October 2026 without additional funding.
The Board is actively pursuing funding and strategic options to strengthen the financial position and extend the cash runway.
Directors acknowledge material uncertainties regarding going concern but believe sufficient cash resources will be available.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Futura Medical
- Strategic reset in 2025 refocused on new product launches, cost control, and APAC growth.FUM
H2 2025 - FY25 revenue beats expectations; cash runway secured through December 2026.FUMQ4 2025 TU
- Weak sales and high losses in H1 2025 prompt strategic review and urgent cost-cutting.FUMH1 2025
- Achieved maiden profit and 300% revenue growth, with major U.S. launch set for October.FUMH1 2024
- 2024 saw maiden profit, strong Eroxon rollout, and pipeline progress, but sales guidance lowered.FUMH2 2024
Next Futura Medical earnings date
H2 202628 Apr, 2027
Futura Medical
Next Futura Medical earnings date
H2 202628 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Futura Medical plc is a UK-based pharmaceutical company developing topical products for sexual health and pain relief. The company uses proprietary transdermal delivery technologies to create over-the-counter and prescription products. It focuses on regulatory approvals and commercial partnerships for global distribution. It is headquartered in Guildford, United Kingdom, and its shares are listed on the LSE.